Significant Revenue Growth
VolitionRX reported a 44% increase in revenue compared to Q1 2024, including the first revenue recorded for sales of human products.
Operating Expenses Reduction
Total operating expenses for the quarter declined 35% compared to Q1 2024, reflecting cost reductions across all spending categories.
Successful Licensing Discussions
VolitionRX is in confidential discussions with over 10 companies to license their products, with seven companies having a combined market value exceeding $600 billion.
Nu.Q Platform Developments
The company is progressing in the commercialization of their Nu.Q platform in the human diagnostic market, with potential market opportunities in cancer and sepsis diagnostics.
First Revenue from CE Marked Product
VolitionRX recorded its first revenue from sales of its CE Marked Nu.Q NETs automated product in Europe.
Expansion of Nu.Q Vet
Nu.Q Vet Cancer Test is expanding its global reach, with significant partnerships in place to enhance canine cancer screening.
Nu.Q Discover Revenue Potential
Nu.Q Discover biomarkers are being utilized in a human clinical study sponsored by a leading pharmaceutical company, expected to generate significant revenue.